Finasteride and methadone use and risk of advanced hepatitis C related liver disease

Donna L. White, Ali Hashmi, David J. Ramsey, Jill Kuzniarek, Shahriar Tavakoli-Tabasi, B. El Serag Hashem

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. Background: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. Methods: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and racestratified multivariate analyses. Results: Among 571 HCV+ males, 43 % were White and 57 % African-American. There were non-significant decreased risks with finasteride use (ORadj advanced fibrosis = 0.75, 95 % CI 0.39-1.45 and ORadj advanced inflammation = 0.74, 95 % CI 0.41-1.43). For methadone, there was a nonsignificant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). Conclusions: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.

Original languageEnglish (US)
Pages (from-to)3004-3010
Number of pages7
JournalDigestive Diseases and Sciences
Volume57
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Finasteride
Methadone
Hepatitis C
Liver Diseases
Fibrosis
Hepacivirus
Inflammation
varespladib methyl
Liver
Veterans
Virus Diseases
African Americans
Androgens
Medical Records
Multivariate Analysis
Cross-Sectional Studies
Pathology

Keywords

  • Drug addiction
  • Epidemiology
  • Hepatology
  • Sex hormones
  • Urology

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

White, D. L., Hashmi, A., Ramsey, D. J., Kuzniarek, J., Tavakoli-Tabasi, S., & Hashem, B. E. S. (2012). Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Digestive Diseases and Sciences, 57(11), 3004-3010. https://doi.org/10.1007/s10620-012-2231-3

Finasteride and methadone use and risk of advanced hepatitis C related liver disease. / White, Donna L.; Hashmi, Ali; Ramsey, David J.; Kuzniarek, Jill; Tavakoli-Tabasi, Shahriar; Hashem, B. El Serag.

In: Digestive Diseases and Sciences, Vol. 57, No. 11, 11.2012, p. 3004-3010.

Research output: Contribution to journalArticle

White, DL, Hashmi, A, Ramsey, DJ, Kuzniarek, J, Tavakoli-Tabasi, S & Hashem, BES 2012, 'Finasteride and methadone use and risk of advanced hepatitis C related liver disease', Digestive Diseases and Sciences, vol. 57, no. 11, pp. 3004-3010. https://doi.org/10.1007/s10620-012-2231-3
White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S, Hashem BES. Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Digestive Diseases and Sciences. 2012 Nov;57(11):3004-3010. https://doi.org/10.1007/s10620-012-2231-3
White, Donna L. ; Hashmi, Ali ; Ramsey, David J. ; Kuzniarek, Jill ; Tavakoli-Tabasi, Shahriar ; Hashem, B. El Serag. / Finasteride and methadone use and risk of advanced hepatitis C related liver disease. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 11. pp. 3004-3010.
@article{68e268624e3f4f3f9acf4770143824d3,
title = "Finasteride and methadone use and risk of advanced hepatitis C related liver disease",
abstract = "Aim We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. Background: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. Methods: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and racestratified multivariate analyses. Results: Among 571 HCV+ males, 43 {\%} were White and 57 {\%} African-American. There were non-significant decreased risks with finasteride use (ORadj advanced fibrosis = 0.75, 95 {\%} CI 0.39-1.45 and ORadj advanced inflammation = 0.74, 95 {\%} CI 0.41-1.43). For methadone, there was a nonsignificant 41 {\%} increased advanced fibrosis risk in Whites and 51 {\%} reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). Conclusions: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.",
keywords = "Drug addiction, Epidemiology, Hepatology, Sex hormones, Urology",
author = "White, {Donna L.} and Ali Hashmi and Ramsey, {David J.} and Jill Kuzniarek and Shahriar Tavakoli-Tabasi and Hashem, {B. El Serag}",
year = "2012",
month = "11",
doi = "10.1007/s10620-012-2231-3",
language = "English (US)",
volume = "57",
pages = "3004--3010",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Finasteride and methadone use and risk of advanced hepatitis C related liver disease

AU - White, Donna L.

AU - Hashmi, Ali

AU - Ramsey, David J.

AU - Kuzniarek, Jill

AU - Tavakoli-Tabasi, Shahriar

AU - Hashem, B. El Serag

PY - 2012/11

Y1 - 2012/11

N2 - Aim We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. Background: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. Methods: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and racestratified multivariate analyses. Results: Among 571 HCV+ males, 43 % were White and 57 % African-American. There were non-significant decreased risks with finasteride use (ORadj advanced fibrosis = 0.75, 95 % CI 0.39-1.45 and ORadj advanced inflammation = 0.74, 95 % CI 0.41-1.43). For methadone, there was a nonsignificant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). Conclusions: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.

AB - Aim We evaluated the association between two medications that alter bioavailable androgen levels, finasteride and methadone, and risk of advanced HCV-related liver disease. Background: Males have strikingly greater cirrhosis risk across disease etiologies, including hepatitis C virus (HCV) infection. Methods: In a cross-sectional study in HCV+ male veterans, we determined medication use by up to 15-year medical record review, and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs. F0-F3, mild fibrosis; and A2/A3-A3, advanced vs. A0-A2, mild inflammation). We performed race-adjusted and racestratified multivariate analyses. Results: Among 571 HCV+ males, 43 % were White and 57 % African-American. There were non-significant decreased risks with finasteride use (ORadj advanced fibrosis = 0.75, 95 % CI 0.39-1.45 and ORadj advanced inflammation = 0.74, 95 % CI 0.41-1.43). For methadone, there was a nonsignificant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA. White male methadone-users had 2.1-fold excess advanced inflammation risk (p = 0.15). Conclusions: Our preliminary study results suggest finasteride use is not significantly associated with a decreased risk of advanced hepatic fibrosis or inflammation in HCV+ males. The ethnically-divergent results for methadone associated fibrosis risk and finding of potentially increased inflammation risk in White males suggests the need for additional research.

KW - Drug addiction

KW - Epidemiology

KW - Hepatology

KW - Sex hormones

KW - Urology

UR - http://www.scopus.com/inward/record.url?scp=84871607859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871607859&partnerID=8YFLogxK

U2 - 10.1007/s10620-012-2231-3

DO - 10.1007/s10620-012-2231-3

M3 - Article

VL - 57

SP - 3004

EP - 3010

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 11

ER -